An implantable pump that has the potential to transform brain cancer treatment was found safe and effective in people in a study at Columbia University.
Many proteins contain patterns of sugar molecules (glycans) and are made of several aggregated subunits.
Reproductive health experts consider hormonal contraceptives good choices for adolescents because they’re safe and highly effective at preventing pregnancy, but one aspect of their effect on the teenage body remains a mystery – whether and how they modify the developing brain.
Mountainside Medical Center is approved to use Pluvicto™, an FDA-approved, targeted radioligand therapy for treatment of metastatic prostate-specific membrane antigen positive castration-resistant prostate cancer. This makes Mountainside the first in the state to offer treatment using Pluvicto™.
A research team led by the University of Houston has developed a vaccine targeting the dangerous synthetic opioid fentanyl that could block its ability to enter the brain, thus eliminating the drug’s “high.”
In a new ‘Ideas and Opinions,’ authors from Johns Hopkins Bloomberg School of Public Health analyze California’s newly announced effort to manufacture insulin for its residents. The commentary is published in Annals of Internal Medicine.
Naltrexone was originally used to help treat alcohol and opioid abuse. However, at lose doses, naltrexone has been found to help with chronic pain stemming from various conditions including fibromyalgia, Crohn’s disease, diabetic neuropathy, axial low back pain, rheumatoid arthritis, and complex region pain syndrome.
Stanford University researchers recently conducted a systematic review of studies on cervical radiculopathy, commonly referred to as “pinched nerve,” to determine if steroids are a safe and effective treatment.
MD Anderson and Exscientia today announced a strategic collaboration to align the drug development expertise of MD Anderson with the patient-centric AI capabilities of Exscientia to advance new targeted cancer therapies.
Traditional Chinese medicine (TCM) has been around for centuries.
Intranasal (in.) administration has been garnering increasing popularity as a non-invasive approach to deliver drugs directly to the brain.
Researchers at UC Riverside are paving the way for diabetes and cancer patients to forget needles and injections, and instead take pills to manage their conditions.
Here are some of the latest articles that have been added to the Arthritis channel on Newswise.
Rutgers scientists among those experts who believe Triethylene glycol (TEG) should become a government approved antiviral
Rutgers research shows how changes in the brain promote drug-seeking behavior and why some insomnia medications may block it
The costliness of drug development and the limitations of studying physiological processes in the lab are two separate scientific issues that may share the same solution.
A normal process called cell competition, in which healthy tissues eliminate unhealthy cells, could be responsible for cancer relapses in patients months or years after they were declared cancer-free
New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, showed that combining a nonsteroidal anti-inflammatory drug and TNF inhibitor did not significantly slow radiographic spinal progression in radiographic axial spondyloarthritis patients.
New research presented this week at ACR Convergence, the organization's annual meeting, found no significant difference in cancer risk in patients with rheumatic disease & a history of malignancy taking biologic or targeted synthetic DMARDs compared to those treated with TNF inhibitors.
New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, found that adult RA patients starting opioids had twice the risk of venous thromboembolism (VTE) compared to patients starting nonsteroidal anti-inflammatory drugs (NSAIDs).
New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual scientific meeting, found that the recommended weight-based or non-weight-based dose of hydroxychloroquine led to more hospitalizations for flares among patients with systemic lupus erythematosus
Research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, described a novel program that offers rheumatoid arthritis (RA) training to primary care providers in the Navajo Nation, the largest American Indian reservation in the United States.
New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, showed that treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and older age were associated with longer time to conception in spondyloarthritis patients.
New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, found that the B-cell inhibitor belimumab significantly improved cutaneous lupus erythematosus (CLE) whether or not patients also had systemic lupus erythematosus (SLE or lupus).
New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, found that the biologic B-cell inhibitor belimumab was associated with a lower risk of severe infections and hospitalizations compared to nonbiologic immunosuppressants.
New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, found no clear association between immunosuppressive or anti-fibrotic medications and worsening gastrointestinal symptoms in early systemic scleroderma.
After showing promise in early laboratory research, the cholesterol-lowering drug fenofibrate had no significant effect on COVID-19 outcomes in a multicenter international randomized clinical trial led by Penn Medicine scientists.
Alzheimer's disease is a risk factor for epilepsy - and epilepsy is a risk factor for Alzheimer's. We spoke with Dr. Andrew Cole and Dr. Alice Lam about the latest research and some intriguing findings that suggest links between these two conditions.
For more than four decades, doctors have been split on whether giving steroids during a pediatric open-heart surgery could be helpful for post-operative recovery. A new study is providing a bit more clarity, suggesting there are some benefits for certain kinds of patients.
In a head-to-head comparison of two so-called ‘water pills’ that keep fluid from building up in patients with heart failure, the therapies proved nearly identical in reducing deaths, according to a large study led by Duke Health researchers.
A ToxSpotlight article in the November 2022 issue of ToxSci assesses the mechanism for cellular accumulation of diglycolic acid while another explores the effect of long-term St. John’s wort administration on acetaminophen-induced acute hepatotoxicity and the involved mechanisms.
A new study, led by experts at the University of Nottingham found that the risk of stomach bleeding caused by using aspirin long-term, can be reduced with a short course of antibiotics, potentially improving the safety of aspirin when used to prevent heart attacks, strokes and possibly some cancers.
CLEVELAND - Considering how patients from different ethnic groups respond to the same drug could be crucial to finding new Alzheimer’s disease treatments – a disorder the Alzheimer’s Association previously deemed a “silent epidemic” among Black adults. A Cleveland Clinic-led study published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association showed that telmisartan, a drug currently prescribed for people with high blood pressure, is associated with a lower risk of Alzheimer’s specifically in Black patients over age 60. Insurance data from millions of adults over age 60 did not show the same potential effect in white patients.
A multicentre clinical trial led by COMPASS Pathways across 22 international sites including Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London and South London and Maudsley NHS Foundation Trust has found that a single 25mg dose of COMP360 psilocybin, alongside psychological support, had a significant impact in reducing symptoms of depression in participants with treatment-resistant depression.
Using human brain organoids, an international team of researchers has shown how the SARS-CoV-2 virus that causes COVID-19 infects cortical neurons and specifically destroys their synapses — the connections between brain cells that allow them to communicate with each other.
As researchers glean new insights into the dynamic inner world of the human immune system, it has become increasingly clear that mitochondria are critical regulators of how our bodies respond to disease.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
The American Society of Anesthesiologists calls on Congress to block a nearly 4.5% Medicare payment cut to anesthesiologists and other physicians included in the Centers for Medicare & Medicaid Services (CMS) 2023 Medicare Physician Fee Schedule (PFS) final rule released yesterday.
A new study led by Ochsner infectious diseases clinical pharmacist Kevin Lin, PharmD, was recently published in PLoS One, suggesting that oral cephalosporins are as safe and effective as the standard of care fluoroquinolones (FQs) for the treatment of acute kidney infections.
A recent analysis indicates that dapagliflozin is a cost-effective treatment in patients with chronic kidney disease in addition to standard of care.
Drug companies and university-based teams are working urgently to find and test new medications that could prevent or slow the decline of brain function in older adults. But a new study suggests they’ll need to work harder to find volunteers for their clinical trials.
Donna Wilcock, Ph.D., of the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) was awarded a $1.7 million National Institutes of Health grant for her lab’s exploration of adverse effects of two new Alzheimer’s disease drugs — aducanumab and lecanemab — which have been shown to slow the progression of cognitive decline.
20240208171546.png&width=400&height=400)
Memorial Sloan Kettering Cancer Center (MSK) announced today that the U.S. Food and Drug Administration (FDA) has approved the oral MEK inhibitor drug cobimetinib (Cotellic®) for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms (HN). These diseases include Erdheim-Chester disease, Rosai-Dorfman disease, and Langerhans cell histiocytosis. Cobimetinib is an oral inhibitor of MEK1 and MEK2, currently approved to treat melanoma.
Binghamton University Assistant Professor of Chemistry Jennifer Hirschi recently received a Maximizing Investigators’ Research Award for $1.93 million from the National Institute of General Medical Sciences to study the mechanisms involved in catalytic reactions.
An analysis of the CHANCE-2 trial has found that persons with normal renal function receive greater benefit from antiplatelet therapy with ticagrelor–aspirin versus clopidogrel–aspirin. The analysis is published in Annals of Internal Medicine.
A study of 50 adult patients with cystic fibrosis (CF) has found that challenged urine bicarbonate excretion may offer a new, simple, and safe quantification of cystic fibrosis transmembrane conductance regulator (CFTR) function and the extent of its pharmacologic improvement. The study is published in Annals of Internal Medicine.
A multinational cohort study of persons with atrial fibrillation (AF) found that compared with all direct oral anticoagulants (DOACs), apixaban was associated with lower rates of gastrointestinal (GI) bleeding but similar rates of ischemic stroke, intracranial hemorrhage (ICH), and all-cause mortality. The findings are published in Annals of Internal Medicine.
UC San Diego researchers and others report that more than one-third of the COVID-19 patients who did not receive any treatment experienced complete resolution of symptoms for at least two consecutive days, but then subsequently reported a return of symptoms.
A new study led by Duke Health found that advanced practice clinicians received more payments from drug companies, while physicians accepted more funds from medical device companies. The same proportion of each group accepted payments, but the physicians received a much greater sum.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
